Recent research from the S: CORT team has identified key biomarkers and treatment strategies that predict and enhance effectiveness of radiotherapy in rectal cancer treatment.
Patients with advanced rectal cancer often receive radiotherapy before surgery. However, despite this being standard practice, this treatment only results in complete disappearance (complete response) prior to surgery in 15% of patients.
Currently, there are no reliable biomarkers (a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease) to predict which colorectal patients will benefit from radiotherapy, meaning that many patients are unnecessarily exposed to significant side effects.
Leave a reply